Project Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Trustees of Boston University a $1.27 million Project Grant (CFDA 93.837—Cardiovascular Diseases Research) on September 2, 2025, to develop the first high-speed wearable speckle contrast optical spectroscopy (SCOS) system for cuffless ambulatory blood pressure monitoring. The project addresses a critical clinical need: while traditional periodic cuff-based blood pressure measurements remain the standard of care,...
This $696,259 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research integrating flexible electronics and optogenetics to enable real-time arrhythmic profiling of engineered heart tissues. Awarded to Northwestern University's Sponsored Research Division on June 1, 2026, with completion targeted for April 30, 2031, the project addresses critical limitations in current cardiac disease modeling by...
This Project Grant award from the National Science Foundation (NSF) under the Engineering program (CFDA 47.041) provides $199,992 to Boston University to develop a high-throughput electrical stimulation screening platform for assessing the long-term effects of cardiac contractility modulation (CCM) devices on engineered human heart tissue. The project will support a postdoctoral scholar co-mentored by researchers at the Food and Drug Administration (FDA) and Boston University to advance...
Grant Award Summary Vivamed, Inc. received a $257,015 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 15, 2026, with completion targeted for April 30, 2028. The company will develop a wirelessly powered, battery-free hypoglossal nerve stimulator (HNS) device for treating obstructive sleep apnea (OSA). The device will incorporate integrated electromyography (EMG) sensors for closed-loop...
Teliatry Inc. received a $768,138 project grant award from the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering to develop a minimally invasive, single incision, rechargeable spinal cord stimulation system for chronic pain management. The grant was awarded under the Discovery and Applied Research for Technological Innovations to Improve Human Health program. Through this award, Teliatry will engineer the world's smallest (0.75cc), most cost-effective...
Dynocardia Inc. received a $256,000 National Science Foundation Project Grant to advance development of a novel continuous, cuffless blood pressure monitoring device. Funded through the NSF Engineering Directorate's SBIR program, the award will support Dynocardia's efforts to address motion artifacts and enable accurate, beat-to-beat blood pressure measurements in hospital intensive care and operating room settings. Accurate 24-hour blood pressure monitoring has potential to significantly...
Federal Grant Award Summary Spheric Bio Inc. received a $598,636 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 25, 2025, with completion targeted for September 14, 2027. The company is developing the EMULAATE platform, a minimally-invasive technology that assembles fully-soft, patient-specific implants directly within the patient's body to occlude the left atrial appendage (LAA) for...
Grant Award Summary The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) awarded a $562,228 Project Grant (CFDA 93.865: Child Health and Human Development Extramural Research) to Kessler Foundation, Inc. effective June 1, 2026, with completion scheduled for May 31, 2028. The award funds a clinical research study investigating the impact of transcutaneous spinal cord stimulation (SCTS) on blood pressure regulation and orthostatic hypotension in individuals...
This $400,000 Project Grant from the National Science Foundation's Division of Electrical, Communications and Cyber Systems, under the Engineering (47.041) federal grant program, will fund research at Georgia Tech Research Corporation to advance implantable bioelectronics for continuous monitoring of vascular health. Specifically, the grant will support understanding of printing soft microstructures for enhanced sensor sensitivity, study of passive wireless sensing principles and 3D...
Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Louisiana State University Health Sciences Center-Shreveport a $479,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025, through August 31, 2028. The award funds research investigating afferent baroreflex dysfunction in hypertension, with a focus on understanding how arterial baroreceptors—sensory neurons that regulate blood pressure through neural...
3D PRINTED SOFT AND STRETCHABLE TISSUE-LIKE BIOADHESIVE ELECTRONIC DEVICE ENABLED NEUROMODULATION FOR RESISTANT HYPERTENSION THERAPY - PROJECT SUMMARY THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP A SOFT AND STRETCHABLE TISSUE-LIKE BIOADHESIVE ELECTRONIC DEVICE FOR THE TREATMENT OF RESISTANT HYPERTENSION. HYPERTENSION IS A MAJOR BURDEN ON HEALTHCARE SYSTEMS AND AN IMPORTANT CONTRIBUTOR TO GLOBAL MORBIDITY AND MORTALITY. ALTHOUGH A NUMBER OF MEDICINES HAVE BEEN USED FOR THE TREATMENT OF HYPERTENSION, A LARGE PORTION OF PATIENTS (MORE THAN 10 MILLION) ARE RESISTANT TO MEDICATIONS. ELECTRICAL ACTIVATION OF THE CAROTID SINUS BAROREFLEX (CSB) HAS BEEN PROVEN TO A PROMISING STRATEGY TO REDUCE BLOOD PRESSURE (BP) IN DRUG-RESISTANT HYPERTENSION PATIENTS. NEVERTHELESS, EXISTING COMMERCIAL DEVICES FOR CSB ACTIVATION HAVE SIGNIFICANT LIMITATIONS THAT PRECLUDES THEIR PRACTICAL APPLICATIONS. THEY ARE STIFF AND UNABLE TO STRETCH IN RESPONSE TO THE CAROTID WALL'S PERIODIC EXPANSION AND CONTRACTION, WHICH CAUSES TISSUE DAMAGE AND INFLAMMATION. BESIDES, THEY ALSO REQUIRE TO BE SUTURED TO THE CAROTID WALL AND INTRODUCE FURTHER DAMAGE. OVERALL, THESE LIMITATIONS OF EXISTING DEVICES CAUSE SIGNIFICANT PATIENT DISCOMFORT, ILLNESS, AND FAILURE OF DEVICES OVER TIME, WHICH PRECLUDES THEIR WIDE APPLICATION IN HYPERTENSION THERAPY. THE DEVELOPMENT OF A MINIMALLY INVASIVE DEVICE FOR LONG-TERM CSB ACTIVATION THAT DOES NOT CAUSE HARM IS AN URGENT UNMET NEED. OUR GOAL IS TO DEVELOP A NEXT- GENERATION DEVICE FOR DRUG-RESISTANT HYPERTENSION THERAPY THAT CAN ENABLE LONG-TERM EFFICIENT, SAFE, AND MINIMALLY INVASIVE NON-PHARMACOLOGICAL NEUROMODULATION THERAPIES FOR HYPERTENSION. WE ADOPT SOFT, STRETCHABLE, YET RESILIENT HYDROGEL-BASED MATERIALS FOR THE FABRICATION OF THE DEVICES TO MATCH THE MECHANICAL PROPERTIES OF TISSUES AND SIGNIFICANTLY REDUCE TISSUE DAMAGE AND INFLAMMATION. OWING TO ITS INTRINSIC STRETCHABILITY, THE WHOLE DEVICE CAN DEFORM WITH THE CONTRACTION AND EXPANSION OF CAROTID WALLS AND THUS MINIMIZE CONSTRAINT AND DAMAGE TO THE CAROTID. WE WILL ALSO ADOPT A BIOADHESIVE COMPONENT IN THE PROPOSED SYSTEM TO ELIMINATE THE NEED FOR SUTURING OF ELECTRICAL DEVICES ON CAROTID WALLS, THUS SIGNIFICANTLY DECREASING THE INVASIVENESS OF IMPLANTED DEVICES AND INCREASING THE STABILITY OF THE DEVICE-TISSUE INTERFACE. WE PROPOSE THE FOLLOWING SPECIFIC AIMS TO ENSURE SUCCESSFUL COMPLETION OF THE PROJECT. AIM 1) TO DEVELOP STRETCHABLE AND PRINTABLE BIOADHESIVE MATERIALS FOR SUTURE-FREE IN VIVO INCORPORATION AND CHARACTERIZATION. WE WILL FABRICATE 3D-PRINTABLE STRETCHABLE BIOADHESIVE MATERIALS TO ENABLE STABLE LONG-TERM INTERFACING BETWEEN MEDICAL DEVICES AND IN VIVO TISSUE. AIM 2) TO OPTIMIZE SOFT AND STRETCHABLE TISSUE-LIKE BIOELECTRONIC DEVICE DESIGNS FOR OPTIMAL LONG-TERM TISSUE-RESPONSE ON DYNAMIC TISSUE. BY OPTIMIZING DEVICE DESIGNS AND MATERIALS, WE WILL IMPROVE THE LONG-TERM TISSUE RESPONSE OF TISSUE-LIKE BIOELECTRONIC DEVICES IMPLANTED ON THE CAROTID SINUS. AIM 3) TO OPTIMIZE THE ACUTE AND LONG-TERM EFFECTIVENESS OF TISSUE-LIKE BIOELECTRONIC DEVICE FOR ELECTRICAL STIMULATION OF CAROTID SINUS BAROREFLEX (CSB). WE HAVE AN INTERDISCIPLINARY TEAM WITH EXPERTISE IN TISSUE-LIKE BIOELECTRONICS, SOFT MATERIALS, BIOADHESIVES, ADDITIVE MANUFACTURING, RESISTANT-HYPERTENSION, AND CAROTID SINUS BAROREFLEX STIMULATION THERAPY FOR TREATMENT OF HYPERTENSION TO GUARANTEE THE SUCCESS OF THIS PROJECT. THE SUCCESS OF THIS WORK WILL PROVIDE A NOVEL DEVICE FOR MINIMALLY INVASIVE AND LONG-TERM ACTIVATION OF THE CAROTID SINUS BAROREFLEX FOR THE TREATMENT OF RESISTANT HYPERTENSION. THIS DEVICE WILL HAVE AN IMPORTANT POSITIVE IMPACT BECAUSE IT INTRODUCES REDUCED TISSUE INFLAMMATION/DAMAGE AND SIGNIFICANTLY INCREASED STABILITY AND SAFETY, WHICH BENEFITS MILLIONS OF HYPERTENSION PATIENTS. 1